TrialBMJ open2020

Cost-effectiveness analysis of adding ramucirumab to the first-line erlotinib treatment for untreated EGFR-mutated metastatic non-small cell lung cancer in China.

Qiao Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.